Ejaz A Ahsan, Asmar Abdo, Alsabbagh Mourad M, Ahsan Nasimul
Department of Nephrology; Hypertension and Transplantation; University of Florida; Gainesville, FL USA.
Department of Clinical Sciences; University of Central Florida; Orlando, FL USA.
MAbs. 2012 Mar-Apr;4(2):198-207. doi: 10.4161/mabs.4.2.19286. Epub 2012 Mar 1.
Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.
实验数据表明，B细胞抗原CD20可能在包括肾小球疾病在内的多种疾病的发病机制中发挥重要作用。这些发现以及其他一些发现支持了以CD20抗原为靶点的B细胞耗竭疗法的核心概念，该疗法可用于治疗狼疮性肾炎、特发性膜性肾病、局灶节段性肾小球硬化症、冷球蛋白血症性肾小球肾炎、抗体介导的肾移植排斥反应以及肾移植中的复发性肾小球肾炎。使用利妥昔单抗作为B细胞耗竭疗法已与临床改善相关联，并已成为肾脏病学领域一种可能的辅助或替代治疗选择。
